共 50 条
[1]
Faulkner KG(1993)Diagnosis, prophyaxis, and treatment of osteoporosis Am. J. Med. 94 646-650
[2]
Guyatt GH(2000)Bone matters. Are density increases necessary to reduce fracture risks? J. Bone Miner. Res. 15 183-187
[3]
Grady D(1998)Evidence-based management of patients with osteoporosis J. Clin. Densitom. 1 395-402
[4]
Herrington D(2002)Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II) JAMA 288 49-57
[5]
Bittner V(2001)Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles Bone 28 524-531
[6]
Mashiba T(2000)Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis Aging Clin. Exp. Res. 12 1-12
[7]
Turner CH(2002)Intravenous zoledronic acid in postmenopausal women with low bone mineral density N. Engl. J. Med. 346 653-661
[8]
Hirano T(2002)Three-monthly 2 mg intravenous ibandronate bolus injections significantly increase bone mineral density in women with postmenopausal osteoporosis Osteoporos. Int. 13 S14-3081
[9]
Forwood MR(1999)Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial J. Clin. Endocrinol. Metab. 84 3076-992
[10]
Johnston CC(2002)Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis J. Clin. Endocrinol. Metab. 87 985-1897